Yuko Nitahara-Kasahara1,2,3, Mutsuki Kuraoka4,5, Posadas Herrera Guillermo6,7, Hiromi Hayashita-Kinoh8,4,7, Yasunobu Maruoka6, Aki Nakamura-Takahasi9, Koichi Kimura4,10, Shin'ichi Takeda4, Takashi Okada11,12,13. 1. Department of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo, Japan. y-kasahara@nms.ac.jp. 2. Division of Cell and Gene Therapy, Nippon Medical School, Bunkyo-city, Tokyo, Japan. y-kasahara@nms.ac.jp. 3. Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan. y-kasahara@nms.ac.jp. 4. Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan. 5. Laboratory of Experimental Animal Science, Nippon Veterinary and Life Science University, Musashino, Tokyo, Japan. 6. Department of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo, Japan. 7. Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, Institute of Medical Science, The University of Tokyo, Minato-city, Tokyo, Japan. 8. Division of Cell and Gene Therapy, Nippon Medical School, Bunkyo-city, Tokyo, Japan. 9. Department of Pharmacology, Tokyo Dental College, Tokyo, Japan. 10. Department of General Medicine, The Institute of Medical Science, The University of Tokyo, Minato-city, Tokyo, Japan. 11. Division of Cell and Gene Therapy, Nippon Medical School, Bunkyo-city, Tokyo, Japan. t-okada@ims.u-tokyo.ac.jp. 12. Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan. t-okada@ims.u-tokyo.ac.jp. 13. Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, Institute of Medical Science, The University of Tokyo, Minato-city, Tokyo, Japan. t-okada@ims.u-tokyo.ac.jp.
Abstract
BACKGROUND: Duchenne muscular dystrophy (DMD) is an inherited progressive disorder that causes skeletal and cardiac muscle deterioration with chronic inflammation. Dental pulp stem cells (DPSCs) are attractive candidates for cell-based strategies for DMD because of their immunosuppressive properties. Therefore, we hypothesized that systemic treatment with DPSCs might show therapeutic benefits as an anti-inflammatory therapy. METHODS: To investigate the potential benefits of DPSC transplantation for DMD, we examined disease progression in a DMD animal model, mdx mice, by comparing them with different systemic treatment conditions. The DPSC-treated model, a canine X-linked muscular dystrophy model in Japan (CXMDJ), which has a severe phenotype similar to that of DMD patients, also underwent comprehensive analysis, including histopathological findings, muscle function, and locomotor activity. RESULTS: We demonstrated a therapeutic strategy for long-term functional recovery in DMD using repeated DPSC administration. DPSC-treated mdx mice and CXMDJ showed no serious adverse events. MRI findings and muscle histology suggested that DPSC treatment downregulated severe inflammation in DMD muscles and demonstrated a milder phenotype after DPSC treatment. DPSC-treated models showed increased recovery in grip-hand strength and improved tetanic force and home cage activity. Interestingly, maintenance of long-term running capability and stabilized cardiac function was also observed in 1-year-old DPSC-treated CXMDJ. CONCLUSIONS: We developed a novel strategy for the safe and effective transplantation of DPSCs for DMD recovery, which included repeated systemic injection to regulate inflammation at a young age. This is the first report on the efficacy of a systemic DPSC treatment, from which we can propose that DPSCs may play an important role in delaying the DMD disease phenotype.
BACKGROUND:Duchenne muscular dystrophy (DMD) is an inherited progressive disorder that causes skeletal and cardiac muscle deterioration with chronic inflammation. Dental pulp stem cells (DPSCs) are attractive candidates for cell-based strategies for DMD because of their immunosuppressive properties. Therefore, we hypothesized that systemic treatment with DPSCs might show therapeutic benefits as an anti-inflammatory therapy. METHODS: To investigate the potential benefits of DPSC transplantation for DMD, we examined disease progression in a DMD animal model, mdx mice, by comparing them with different systemic treatment conditions. The DPSC-treated model, a canineX-linked muscular dystrophy model in Japan (CXMDJ), which has a severe phenotype similar to that of DMDpatients, also underwent comprehensive analysis, including histopathological findings, muscle function, and locomotor activity. RESULTS: We demonstrated a therapeutic strategy for long-term functional recovery in DMD using repeated DPSC administration. DPSC-treated mdx mice and CXMDJ showed no serious adverse events. MRI findings and muscle histology suggested that DPSC treatment downregulated severe inflammation in DMD muscles and demonstrated a milder phenotype after DPSC treatment. DPSC-treated models showed increased recovery in grip-hand strength and improved tetanic force and home cage activity. Interestingly, maintenance of long-term running capability and stabilized cardiac function was also observed in 1-year-old DPSC-treated CXMDJ. CONCLUSIONS: We developed a novel strategy for the safe and effective transplantation of DPSCs for DMD recovery, which included repeated systemic injection to regulate inflammation at a young age. This is the first report on the efficacy of a systemic DPSC treatment, from which we can propose that DPSCs may play an important role in delaying the DMD disease phenotype.
Authors: Martin K Childers; Carol S Okamura; Daniel J Bogan; Janet R Bogan; Gregory F Petroski; Kerry McDonald; Joe N Kornegay Journal: Arch Phys Med Rehabil Date: 2002-11 Impact factor: 3.966
Authors: Peter Stanko; Katarina Kaiserova; Veronika Altanerova; Cestmir Altaner Journal: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Date: 2013-10-18 Impact factor: 1.245
Authors: Ben Mead; Martin Berry; Ann Logan; Robert A H Scott; Wendy Leadbeater; Ben A Scheven Journal: Stem Cell Res Date: 2015-02-24 Impact factor: 2.020
Authors: Alejandro Galán-Mercant; Francisco Javier Barón-López; María T Labajos-Manzanares; Antonio I Cuesta-Vargas Journal: Biomed Eng Online Date: 2014-12-02 Impact factor: 2.819